Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alvin Cacho

Cardiovascular Disease Stockton, CA Medical Doctor

NPI 1205918497 CMS profile 54717

2800 N California St Ste 14, Ste 1, Stockton, CA 95204

Open in the dashboard

General payments

$13,414

626 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alvin Cacho of Stockton, CA is reported in the CMS Open Payments database as having received $13,414 across 626 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,132 49
2024 General $1,024 46
2023 General $1,059 40
2022 General $2,649 108
2021 General $2,727 166
2020 General $1,545 89
2019 General $3,278 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alvin Cacho
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Alvin Cacho were reported at $1,132. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Alvin Cacho Cardiovascular Disease median Middle half National median
2019 $3,278 $450 $127–$1,392 $163
2020 $1,545 $242 $77–$751 $114
2021 $2,727 $335 $101–$1,037 $132
2022 $2,649 $395 $121–$1,211 $149
2023 $1,059 $443 $136–$1,283 $160
2024 $1,024 $450 $136–$1,323 $164
2025 $1,132 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,440 45 payments
  2. Novartis Pharmaceuticals Corporation $1,225 82 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,153 63 payments
  4. Janssen Pharmaceuticals, Inc $1,124 69 payments
  5. Boston Scientific Corporation $998 18 payments
  6. Amgen Inc. $742 37 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $589 26 payments
  8. Pfizer Inc. $571 24 payments
  9. E.R. Squibb & Sons, L.L.C. $428 20 payments
  10. Merck Sharp & Dohme Corporation $413 13 payments
  11. Other $4,732 229 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,171 613 payments
  2. Travel and Lodging $560 2 payments
  3. Education $555 9 payments
  4. Debt forgiveness $128 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,124 69 payments
  2. JARDIANCE $945 52 payments
  3. WATCHMAN $821 4 payments
  4. FARXIGA $812 32 payments
  5. Repatha $699 35 payments
  6. ENTRESTO $648 43 payments
  7. Kerendia $520 22 payments
  8. ELIQUIS $451 22 payments
  9. VERQUVO $433 14 payments
  10. NEXLETOL $392 27 payments
  11. Other $6,816 346 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

5,243

Median for Cardiology: 2,533

Drug cost

$724,454

Median for Cardiology: $485,213

Branded share of claims

32.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 230 $202,573
Xarelto Rivaroxaban Brand 152 $143,970
Jardiance Empagliflozin Brand 87 $82,913
Entresto Sacubitril/Valsartan Brand 35 $35,885
Farxiga Dapagliflozin Propanediol Brand 30 $33,845
Tradjenta Linagliptin Brand 30 $25,345
Repatha Sureclick Evolocumab Brand 45 $24,395
Ozempic Semaglutide Brand 24 $20,305
Vascepa Icosapent Ethyl Brand 33 $16,579
Multaq Dronedarone Hcl Brand 17 $16,132

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $202
$202 45 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $129
$129 87 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $61
$61 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

626 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record